Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Technological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
World J Urol
January 2025
Department of Urology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China.
Purpose: The purpose of this study was to investigate the efficacy of Transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology in the treatment of benign prostatic hyperplasia (BPH), with a focus on preserving sexual function postoperatively.
Methods: Conducted as a multicenter, prospective, single-blind randomized controlled trial, this study enrolled sexually active male patients with BPH. Participants were randomized into three groups: standard HoLEP (Group A), single-n technology (Group B), and innovative double-n technology (Group C), which emphasizes the preservation of the urethral mucosa and nearby structures.
Background: Renal atrophy may reflect an end organ consequence of chronic vascular disease. Renal volume loss may therefore provide a window into brain aging and Alzheimer disease risk.
Method: We obtained whole-body 1.
A novel suture-free nephroplication with 4D-printed biodegradable bag for giant hydronephrosis: initial experience from hydromechanics and clinical application.
Int J Surg
January 2025
Department of Urology, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi, China.
Background: Giant hydronephrosis as an rare condition is often caused by chronic ureteral obstruction. Nephroplication is a crucial procedure to improve urinary drainage in the kidney-sparing surgery for patients with giant hydronephrosis. However, traditional nephroplication via suturing kidney has technical difficulty and many potential risks.
View Article and Find Full Text PDFBackground: Renal atrophy may reflect an end organ consequence of chronic vascular disease. Renal volume loss may therefore provide a window into brain aging and Alzheimer disease risk.
Method: We obtained whole-body 1.
Multiple myeloma-associated non-crystalline proximal tubulopathy and crystalline cast nephropathy: Biochemical and structural features of disease-causing monoclonal kappa light chains.
FASEB J
January 2025
Department of Hematology, Nephrology, and Rheumatology, Graduate School of Medicine, Akita University, Akita, Japan.
Various tubular diseases in patients with multiple myeloma (MM) are caused by monoclonal immunoglobulin light chains (LCs). However, the physicochemical characteristics of the disease-causing LCs contributing to the onset of MM-associated tubular diseases remain unclear. We herein report a rare case of MM-associated combined tubulopathies: non-crystalline light chain proximal tubulopathy (LCPT) and crystalline light chain cast nephropathy (LCCN).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!